Nuron Biotech has licensed a gene-based amyloid beta 42 (Aβ42) #vaccine

In Antibodies, Clinical Trials by Katie BardenLeave a Comment

vaccine amyloid beta 42 in preclinical development Nuron Biotech has licensed from Vitruvian BioMedical a gene-based amyloid beta 42 (Aβ42) vaccine that is in preclinical development for Alzheimer disease. The vaccine contains a piece of the gene coding for the amyloid beta protein and works by stimulating an immune response where antibodies are produced which bind to and reduce amyloid beta. Under the agreement, Nuron is responsible for development and commercialization of the vaccine.

According to Pharmaceutical Business Review Nuron Biotech chief executive officer and founder Shankar Musunuri said: “This unique, promising vaccine candidate brings more opportunity to our pipeline and is one of the most promising new advances to improve the lives of Alzheimer’s patients worldwide.”

Leave a Comment

Current ye@r *